1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Wockhardt Limited

Wockhardt Limited

WOCKPHARMA.NS
Wockhardt LimitedIN flagNational Stock Exchange of India
1,810.70
INR
-20.60
- -
294.22BMarket Cap
Wockhardt Limited
WOCKPHARMA.NS
(National Stock Exchange of India)

Recent

price

1,810.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
315.88
366.34
472.18
405.8
375.48
371.76
334.69
325.66
295.4
235.8
224.65
266.26
183.67
193.34
193.54
- -
192.55
Revenue per Share
7.62
28.76
134.19
70.63
33.92
20.93
-16.32
-50.69
-16.2
-5.76
57.1
-20.24
-38.8
-32.1
-3.02
- -
-7.87
Basic EPS, GAAP
28.75
86.42
100.25
85.17
-7.17
-35.09
-56.7
-19.92
-7.62
39.67
-37.7
16.67
-3.89
0.21
-24.87
- -
- -
Free Cash Flow per Basic Share
0.01
0.01
0.04
13.76
20.57
0.02
11.52
0.01
- -
- -
0.08
0.17
- -
- -
- -
- -
- -
Dividend per Share
89.96
55
4.61
4.61
205.1
196.99
175.98
126.87
109.82
103.59
131.84
111.81
54.28
21.98
17.28
- -
- -
Book Value per Share
-86.85
-97.79
131.85
207
228.55
245.65
218.05
155.38
127.03
107.03
162.39
187.29
105.3
94.83
136.16
- -
- -
Tangible Book Value per Share
119
119
119
119
119
120
120
120
120
120
120
121
144
144
156
- -
156
Basic Weighted Avg Shares
37,512
43,505
56,094
48,304
44,815
44,532
40,146
39,077
35,474
28,330
26,990
32,100
26,460
27,890
30,120
33,730
30,110
Sales/Revenue/Turnover
21.63
28.96
35.09
17.39
15.21
8.25
-3.06
-5.24
-4.99
-4.31
-11.37
1.59
-5.63
-1.9
5.98
11.95
6.21
Operating Margin (%)
1,166
1,225
1,248
1,399
1,454
1,419
1,489
1,495
1,660
2,257
2,460
2,470
2,510
2,230
2,170
2,270
2,190
Depreciation Expense
905
3,416
15,941
8,407
4,049
2,507
-1,957
-6,083
-1,945
-692
6,860
-2,440
-5,590
-4,630
-470
2,130
-1,230
Net Income, GAAP
8.29
42.54
14.05
5.38
28.27
13.09
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.39
4.76
Effective Tax Rate (%)
2.41
7.85
28.42
17.4
9.04
5.63
-4.88
-15.57
-5.48
-2.44
25.42
-7.6
-21.13
-16.6
-1.56
6.31
-4.09
Profit Margin (%)
-168
5,906
15,534
16,127
16,885
21,100
25,565
6,879
-490
-10,674
-6,960
-6,180
-12,270
-6,070
5,270
10,750
- -
Working Capital
27,945
27,064
14,752
11,023
14,270
19,206
31,903
21,731
18,915
15,474
7,820
6,220
4,500
10,610
13,060
15,560
- -
LT Debt
9,431
14,710
27,042
37,176
38,341
42,404
37,186
31,979
30,046
30,575
37,590
42,020
36,620
36,620
46,570
52,810
- -
Total Equity
16.57
16.02
35.11
15.43
8.49
5.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.81
- -
Return on Invested Capital (%)
7.25
10.83
47.81
38.06
11.56
6.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.44
- -
Return on Capital (%)
9.51
39.69
450.39
1,533.16
32.36
10.43
-8.76
-33.49
-13.69
-5.4
48.5
-16.64
-52.49
-84.26
-16.04
121.71
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
7,150
- -
LT Borrowings
- -
12,110
- -
LT Finance Leases
- -
950
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
162
- -
Market Capitalization
212,940
217,260
268,023

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
25,690
- -
Cash, Cash Equivalents & STI
- -
5,340
- -
Accounts Receivable, Net
- -
6,610
- -
Inventories
- -
7,250
- -
Total Current Liabilities
- -
20,420
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
7,150
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
13.4%
Free Cash Flow
-1,436.47%
-2,696.86%
-106.72%
Net Income, GAAP
-185.74%
-133.34%
-553.19%
Sales/Revenue/Turnover
-1.99%
5.35%
11.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,440
7,530
7,010
6,910
27,890
2025
7,390
8,090
7,210
7,430
30,120
2026
7,380
8,880
9,650
- -
33,730

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9.28
-5.37
-5.75
- -
-32.1
2025
-0.95
-1.47
0.91
-1.57
-3.02
2026
-5.53
3.61
10.23
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Redwood Scientific Technologies, Inc. (RSCI)
Medivir AB (publ) (0GP7.L)
Vivesto AB (0N4A.L)
Sino Biopharmaceutical Limited (1177.HK)
Godavari Drugs Limited (GODAVARI.BO)
Shandong Xinhua Pharmaceutical Company Limited (000756.SZ)
Business
Wockhardt Limited is a research-based global pharmaceutical and biotechnology company headquartered in Aurangabad, Maharashtra, India, founded in 1960. The company manufactures, markets, and distributes a broad portfolio of products including branded and generic pharmaceuticals, biopharmaceuticals, sterile injectables, and diabetic care products. Its product offerings encompass therapeutic categories such as anti-infectives, oncology, cardiology, diabetes management, and nutritional products. Wockhardt serves markets in over 75 countries, with significant operations in India, the United States, Europe, and emerging markets. The company operates through multiple business segments: pharmaceutical formulations, biotechnology products including biosimilars and complex generics, specialty injectables, and advanced diabetic care solutions consisting of both medications and monitoring devices. Wockhardt leverages cutting-edge research and development capabilities, investing approximately 8-10% of revenues into innovation to advance new product launches, especially in oncology and biologics. Its manufacturing network is designed to meet stringent global regulatory standards. Recent major changes include the acceptance of its New Drug Application (NDA) for Zaynich, India’s first novel chemical entity, by the US Food and Drug Administration (USFDA), with commercial preparations underway particularly targeting the US market alongside planned launches in India, Europe, and emerging markets by mid-2026. The company has also pursued strategic expansions and partnerships in advanced product portfolios and biosimilars to enhance its global footprint. Financially, Wockhardt reported consolidated revenues of approximately ₹2,329 crore in FY 2023 with a net profit of ₹180 crore, demonstrating operational resilience and growth. Wockhardt remains controlled by the founding Khorakiwala family and is led by key executives including Habil Khorakiwala as Chairman. It continues to focus on innovation-driven growth in the global pharmaceutical and biotechnology sectors, emphasizing affordable, high-quality medicines, and advanced healthcare solutions for chronic diseases and complex conditions. Overall, Wockhardt Limited represents a comprehensive pharmaceutical and biotechnology enterprise with a diversified global product offering, ongoing strategic initiatives in novel drug and biosimilar development, and a robust R&D-led approach to expanding its market presence worldwide.